PE20150091A1 - Anticuerpos anti-sez6 y metodos de empleo - Google Patents

Anticuerpos anti-sez6 y metodos de empleo

Info

Publication number
PE20150091A1
PE20150091A1 PE2014001301A PE2014001301A PE20150091A1 PE 20150091 A1 PE20150091 A1 PE 20150091A1 PE 2014001301 A PE2014001301 A PE 2014001301A PE 2014001301 A PE2014001301 A PE 2014001301A PE 20150091 A1 PE20150091 A1 PE 20150091A1
Authority
PE
Peru
Prior art keywords
modulator
methods
sez6
antibody
refers
Prior art date
Application number
PE2014001301A
Other languages
English (en)
Inventor
Laura Saunders
Scott J Dylla
Orit Foord
Robert A Stull
Michael Torgov
Hui Shao
David Liu
Original Assignee
Stem Centrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Centrx Inc filed Critical Stem Centrx Inc
Publication of PE20150091A1 publication Critical patent/PE20150091A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN MODULADOR DE SEZ6 AISLADO QUE COMPRENDE UN ANTICUERPO O UN FRAGMENTO INMUNORREACTIVO DE ESTE. TAMBIEN REFIERE A UN CONJUGADO DE ANTICUERPO-FARMACO DE FORMULA: M-[L-D]N, DONDE: M ES UN MODULADOR DE SEZ6; L ES UN CONECTOR OPCIONAL; D ES UN AGENTE ANTIPROLIFERATIVO; Y N ES UN NUMERO ENTERO ENTRE 1 Y 20. DICHO MODULADOR ES UTIL EN EL TRATAMIENTO DE TRANSTORNOS PROLIFERATIVOS COMO CANCER.
PE2014001301A 2012-02-24 2013-02-22 Anticuerpos anti-sez6 y metodos de empleo PE20150091A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261603203P 2012-02-24 2012-02-24

Publications (1)

Publication Number Publication Date
PE20150091A1 true PE20150091A1 (es) 2015-02-16

Family

ID=47790548

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001301A PE20150091A1 (es) 2012-02-24 2013-02-22 Anticuerpos anti-sez6 y metodos de empleo

Country Status (21)

Country Link
US (3) US9676850B2 (es)
EP (2) EP3539985A1 (es)
JP (2) JP6401060B2 (es)
KR (1) KR102099073B1 (es)
CN (2) CN104334580B (es)
AU (3) AU2013203506B2 (es)
CA (1) CA2865415C (es)
CL (2) CL2014002237A1 (es)
CO (1) CO7151485A2 (es)
ES (1) ES2741936T3 (es)
HK (1) HK1205517A1 (es)
IL (1) IL234208B (es)
MX (2) MX2014010094A (es)
MY (1) MY178120A (es)
NZ (1) NZ631197A (es)
PE (1) PE20150091A1 (es)
PH (1) PH12014501914B1 (es)
RU (1) RU2691698C2 (es)
SG (2) SG10201801444WA (es)
WO (1) WO2013126810A1 (es)
ZA (1) ZA201406967B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201801444WA (en) * 2012-02-24 2018-04-27 Abbvie Stemcentrx Llc Anti sez6 antibodies and methods of use
US11531028B2 (en) * 2013-05-10 2022-12-20 Nordic Bioscience A/S Collagen type X alpha-1 assay
CN105848671B (zh) * 2013-08-28 2019-12-13 艾伯维施特姆森特克斯有限责任公司 位点特异性抗体缀合方法和组合物
KR20160046914A (ko) * 2013-08-28 2016-04-29 스템센트알엑스 인코포레이티드 신규한 ｓｅｚ6 조절물질 및 사용방법
US9381205B2 (en) 2013-11-04 2016-07-05 Pfizer, Inc. Anti-EFNA4 antibody-drug conjugates
SG11201604503XA (en) * 2013-12-03 2016-07-28 Agency Science Tech & Res Cytotoxic antibody
CN106459956B (zh) 2014-01-29 2019-12-17 一般财团法人化学及血清疗法研究所 抗-运甲状腺素蛋白人抗体
US10604562B2 (en) 2014-01-29 2020-03-31 Km Biologics Co., Ltd. Anti-transthyretin humanized antibody
MX2016010677A (es) 2014-02-21 2017-04-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma.
US9631024B2 (en) 2014-06-23 2017-04-25 Bionomics, Inc. Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors
TW201617368A (zh) * 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
EP3204414A4 (en) * 2014-10-07 2018-03-21 Ann and Robert H. Lurie Children's Hospital of Chicago Novel anti-nodal antibodies and methods of using same
MX2018002166A (es) * 2015-08-20 2018-09-12 Abbvie Stemcentrx Llc Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
EP3361280B1 (en) 2015-10-06 2021-12-01 Pioneer Corporation Light control device, light control method, and program
WO2017087547A1 (en) * 2015-11-17 2017-05-26 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
MY191649A (en) 2016-03-04 2022-07-05 Jn Biosciences Llc Antibodies to tigit
US11214612B2 (en) 2016-10-14 2022-01-04 Nima Acquisition, Llc Anti-gliadin antibodies, encoding nucleic acids and methods of detecting gliadin
US11066471B2 (en) * 2016-10-19 2021-07-20 Novelogics Biotechnology Inc. Antibodies to MICA and MICB proteins
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
CN118271442A (zh) 2016-12-23 2024-07-02 蓝鳍生物医药公司 抗sez6l2抗体和抗体药物缀合物
EP3424527A1 (de) * 2017-07-07 2019-01-09 AVA Lifescience GmbH Diagnostisches verfahren
JP7278623B2 (ja) * 2018-04-13 2023-05-22 ディンフー バイオターゲット カンパニー リミテッド 抗ｃｄ２７抗体およびその使用
DK3710485T3 (da) 2018-05-30 2021-05-10 Abbvie Stemcentrx Llc Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder
WO2020013644A1 (ko) * 2018-07-11 2020-01-16 고려대학교 산학협력단 Smo 단백질의 특이적 에피토프, 이를 인지하는 항체 및 이를 포함하는 조성물
CN115991781A (zh) * 2018-08-24 2023-04-21 江苏恒瑞医药股份有限公司 结合人il-4r的抗体、其抗原结合片段及其医药用途
PE20231078A1 (es) 2020-06-02 2023-07-17 Arcus Biosciences Inc Anticuerpos anti-tigit
CN114106176B (zh) * 2020-09-01 2024-04-09 深圳市菲鹏生物治疗股份有限公司 Cd22抗体及其应用
WO2022051223A1 (en) * 2020-09-02 2022-03-10 The Feinstein Institutes For Medical Research Use of sars-cov-2 receptor binding motif (rbm)-reactive monoclonal antibodies to treat covid-19
CN116761635A (zh) 2020-11-24 2023-09-15 诺华股份有限公司 Bcl-xl抑制剂抗体药物缀合物及其使用方法
CN114790241A (zh) * 2021-01-26 2022-07-26 北京免疫方舟医药科技有限公司 抗tigit抗体及其应用
CN113307875B (zh) * 2021-06-10 2022-09-02 福州迈新生物技术开发有限公司 抗TCRβF1蛋白单克隆抗体及其细胞株、制备方法和应用
WO2023019174A2 (en) * 2021-08-11 2023-02-16 Apollos Diagnostics, Llc Antibodies to sars-cov-2
TW202408588A (zh) 2022-05-20 2024-03-01 瑞士商諾華公司 抗體-藥物結合物抗腫瘤化合物及其使用方法
WO2023223097A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody drug conjugates
CN115975036B (zh) * 2022-08-18 2023-06-09 北京诺赛国际医学研究院 包含干细胞的药物组合物及其治疗癌症的用途
CN117736331B (zh) * 2024-02-04 2024-05-07 南昌大学第一附属医院 一种特异性结合psma胞外段的单克隆抗体及其应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
CN1117155C (zh) 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
PT1413582E (pt) 1998-08-27 2006-07-31 Spirogen Ltd Pirrolobenzodiazepinas dimericas
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US20040067490A1 (en) * 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1290026A2 (en) * 2000-04-28 2003-03-12 Eli Lilly And Company Human sez6 nucleic acids and polypeptides
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
US6362331B1 (en) 2001-03-30 2002-03-26 Council Of Scientific And Industrial Research Process for the preparation of antitumor agents
US20030211991A1 (en) * 2001-04-17 2003-11-13 Su Eric Wen Human sez6 nucleic acids and polypeptides
CN1343774A (zh) 2001-05-28 2002-04-10 复旦大学 一种癫痫相关蛋白编码序列,其编码的多肽、制法及用途
JP2005533001A (ja) 2002-03-04 2005-11-04 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
EP1633784B1 (en) 2003-05-09 2011-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
SI1725249T1 (sl) 2003-11-06 2014-04-30 Seattle Genetics, Inc. Spojine monometilvalina, sposobne konjugacije na ligande
GB0404577D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
SI1720881T1 (sl) 2004-03-01 2013-04-30 Spirogen Sarl 11-hidroksi-5H-pirolo(2,1-c)(1,4)benzodiazepin-5onski derivati kot ključni intermediati za pipravo C2 substituiranih pirolobenzodiazepinov
US7189710B2 (en) 2004-03-30 2007-03-13 Council Of Scientific And Industrial Research C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
FR2869231B1 (fr) 2004-04-27 2008-03-14 Sod Conseils Rech Applic Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
WO2006034488A2 (en) 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20070123448A1 (en) 2005-11-23 2007-05-31 The Hospital For Sick Children Novel chemical entities affecting neuroblastoma tumor-initiating cells
ATE527262T1 (de) 2006-01-25 2011-10-15 Sanofi Sa Neue tomaymycin derivate enhaltende zytotoxische mittel
WO2007145901A1 (en) 2006-06-06 2007-12-21 University Of Tennessee Research Foundation Compositions enriched in neoplastic stem cells and methods comprising same
CN103709252B (zh) 2006-06-07 2016-12-07 生物联合公司 识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
EP3207941B3 (en) 2006-09-07 2020-08-19 Scott & White Memorial Hospital Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
CA2675521C (en) 2007-01-22 2016-04-26 Raven Biotechnologies Human cancer stem cells
KR101586617B1 (ko) * 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
EP2764874A1 (en) 2007-07-17 2014-08-13 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic stem cells and uses thereof
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
WO2009043051A2 (en) 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
MX2010007767A (es) 2008-01-18 2010-08-09 Medimmune Llc Anticuerpos manipulados con cisteina para conjugacion especifica de sitio.
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US20100162416A1 (en) 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
WO2010081171A2 (en) 2009-01-12 2010-07-15 Cyntellect, Inc. Laser mediated sectioning and transfer of cell colonies
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
NZ598929A (en) 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
AR080513A1 (es) * 2010-03-12 2012-04-11 Inmunogen Inc Moleculas de union cd37 y sus inmunoconjugados
AU2011239522B2 (en) 2010-04-15 2014-10-23 Medimmune Limited Targeted pyrrolobenzodiazapine conjugates
GB201006340D0 (en) 2010-04-15 2010-06-02 Spirogen Ltd Synthesis method and intermediates
AU2011239525B2 (en) 2010-04-15 2015-04-09 Medimmune Limited Pyrrolobenzodiazepines used to treat proliferative diseases
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
US20120100560A1 (en) 2010-07-23 2012-04-26 The Johns Hopkins University Device for capture, enumeration, and profiling of circulating tumor cells
WO2012019060A1 (en) * 2010-08-05 2012-02-09 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
US20130061342A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
SG189212A1 (en) 2010-09-03 2013-05-31 Stem Centrx Inc Identification and enrichment of cell subpopulations
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US20130061340A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
TWI814373B (zh) 2010-09-29 2023-09-01 美商艾澤西公司 與191p4d12蛋白結合之抗體藥物共軛物(adc)
SG10201801444WA (en) * 2012-02-24 2018-04-27 Abbvie Stemcentrx Llc Anti sez6 antibodies and methods of use
CN105848671B (zh) 2013-08-28 2019-12-13 艾伯维施特姆森特克斯有限责任公司 位点特异性抗体缀合方法和组合物
KR20160046914A (ko) * 2013-08-28 2016-04-29 스템센트알엑스 인코포레이티드 신규한 ｓｅｚ6 조절물질 및 사용방법
US20190209704A1 (en) 2014-10-20 2019-07-11 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions and methods of use
MA41645A (fr) * 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
CN118271442A (zh) 2016-12-23 2024-07-02 蓝鳍生物医药公司 抗sez6l2抗体和抗体药物缀合物

Also Published As

Publication number Publication date
CA2865415A1 (en) 2013-08-29
CO7151485A2 (es) 2014-12-29
JP6401060B2 (ja) 2018-10-03
MX2014010094A (es) 2014-09-16
US9676850B2 (en) 2017-06-13
KR102099073B1 (ko) 2020-04-10
NZ631197A (en) 2017-05-26
SG11201405130UA (en) 2014-11-27
EP2817339B1 (en) 2019-05-15
US20170369571A1 (en) 2017-12-28
IL234208B (en) 2020-11-30
EP3539985A1 (en) 2019-09-18
RU2691698C2 (ru) 2019-06-17
KR20150002621A (ko) 2015-01-07
HK1205517A1 (en) 2015-12-18
CN104334580A (zh) 2015-02-04
WO2013126810A1 (en) 2013-08-29
PH12014501914A1 (en) 2014-11-24
ES2741936T3 (es) 2020-02-12
AU2018223053B2 (en) 2020-05-14
AU2016225828A1 (en) 2016-09-22
CA2865415C (en) 2022-06-21
CN108383909A (zh) 2018-08-10
CL2017002823A1 (es) 2018-03-23
ZA201406967B (en) 2021-06-30
MX2020003713A (es) 2020-07-22
AU2013203506A1 (en) 2013-09-12
CN108383909B (zh) 2021-08-24
EP2817339A1 (en) 2014-12-31
AU2016225828B2 (en) 2018-05-31
MY178120A (en) 2020-10-05
RU2014138420A (ru) 2016-04-10
US20150018531A1 (en) 2015-01-15
SG10201801444WA (en) 2018-04-27
JP2015509948A (ja) 2015-04-02
AU2013203506B2 (en) 2016-06-09
US20200181256A1 (en) 2020-06-11
CN104334580B (zh) 2018-03-30
AU2018223053A1 (en) 2018-09-20
CL2014002237A1 (es) 2015-05-15
PH12014501914B1 (en) 2014-11-24
US10533051B2 (en) 2020-01-14
JP2018127469A (ja) 2018-08-16
BR112014020816A2 (pt) 2017-10-10

Similar Documents

Publication Publication Date Title
PE20150091A1 (es) Anticuerpos anti-sez6 y metodos de empleo
PE20150090A1 (es) Moduladores y metodos de empleo novedosos referencia cruzada a solicitudes
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
BR112019005247A2 (pt) terapia para o câncer resistente a fármacos por meio de administração de conjugado de anticorpo anti-her2/fármaco
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
MX2016003660A (es) Conjugados de partícula similar a virus para el diagnóstico y tratamiento de tumores.
EA201591317A1 (ru) Соединения тубулизина, способы их получения и применение
BR112017020952A2 (pt) método de tratamento de câncer, composição e uso da composição
TN2015000396A1 (en) Antibody drug conjugates
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
PH12016500137A1 (en) Afucosylated anti-fgfr2iiib antibodies
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
MX2016013857A (es) Anticuerpos anti-rnf43 novedosos y metodos de uso.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
WO2014163714A3 (en) Antibody drug conjugates
MX2015014379A (es) Composiciones y metodos para deteccion y tratamiento de carcinoma hepatocelular.
MX2015002482A (es) Composicion inmunogenica.
MX2016013704A (es) Conjugado farmaco-anticuerpo igf-1r y su uso para el tratamiento contra el cancer.
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
WO2017177199A3 (en) Plectin-1 binding antibodies and uses thereof
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
BR112012027393A2 (pt) composto da fórmula geral i, composição farmacêutica, uso de um composto e método de tratamento de qualquer mamífero, notadamente um humano, afetado por câncer

Legal Events

Date Code Title Description
FG Grant, registration